Novo Nordisk Could Raise Guidance Alongside Strong Results -- Market Talk
Dow Jones2026/10/05 08:030802 GMT - Novo Nordisk will likely report a strong set of third-quarter results and raise full-year guidance, J. P. Morgan analysts write. The bank forecasts adjusted sales of 76 billion Danish kroner, 4% ahead of Bloomberg consensus. It expects injectable Wegovy sales of 21.5 billion kroner, 9% ahead of consensus, reflecting continued growth in sales outside the U.S. Oral Wegovy sales are seen at 5.3 billion kroner, 19% ahead of views, as it says consensus seems to be underestimating sales outside the U.S. Ozempic sales are seen at 26.6 billion kroner, 7% ahead of consensus. Adjusted operating profit is seen at 30 billion kroner. The bank also expects Novo to raise its constant exchange rate guidance for adjusted sales and adjusted operating profit to minus 3% to plus 1%, from 0% to minus 6%. Shares fall 1.5%. (dominic.chopping@wsj.com) (END) Dow Jones Newswires October 05, 2026 04:03 ET (08:03 GMT)
0802 GMT - Novo Nordisk will likely report a strong set of third-quarter results and raise full-year guidance, J. P. Morgan analysts write. The bank forecasts adjusted sales of 76 billion Danish kroner, 4% ahead of Bloomberg consensus. It expects injectable Wegovy sales of 21.5 billion kroner, 9% ahead of consensus, reflecting continued growth in sales outside the U.S. Oral Wegovy sales are seen at 5.3 billion kroner, 19% ahead of views, as it says consensus seems to be underestimating sales outside the U.S. Ozempic sales are seen at 26.6 billion kroner, 7% ahead of consensus. Adjusted operating profit is seen at 30 billion kroner. The bank also expects Novo to raise its constant exchange rate guidance for adjusted sales and adjusted operating profit to minus 3% to plus 1%, from 0% to minus 6%. Shares fall 1.5%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
October 05, 2026 04:03 ET (08:03 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
This AI Stock Exploded 600% in a Year, Beating Nvidia and Micron
House Finance panel chair says regulator actions on crypto ‘fall short’ of CLARITY bill
Vietnam: Strong GDP but rising inflation risks – Commerzbank
Incordex appoints Chen Wang to board of directors
Incordex appointed Chen Wang to its board effective Sept. 29, 2026. Wang founded his own brand. He has served as founder and board chairman of Yunnan Jinshengchang Technology and Trade since Oct. 2024. He previously led global pharmaceutical education operations at Meixin E-commerce. He later ran education operations at Zhuyuan Grop. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incordex Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-006080), on October 07, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
